Connect with us

Health

ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients – FiercePharma

Bayer and J&J last year showed their legacy blood thinner Xarelto could help post-surgery patients in tough-to-treat artery disease. Now, the partners have data…

Published

on

Article feature image

With an approval filing already on the FDAs docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients after surgery.
In long-term data from its pivotal trial in peripheral artery disease, Xarelto plus aspirin cut the risk of a variety of clot-related episodesacute clots in the limbs, a major amputation for vascular reasons, heart attack, stroke or cardiovascular deathby 14% compared with aspirin alone in patients who’d had surgery…

Click here to view the original article.

You might also like ...

Article feature image
High fat diets and risk of colorectal cancer – Recent study finds link – Times Now
Article feature image
Turkey intensifies COVID-19 vaccination efforts as age lowered | Daily Sabah – Daily Sabah
Article feature image
Too much coffee triples the risk of blinding eye disease. How much is too much? – Ladders